Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer.

Eilertsen IA, Moosavi SH, Strømme JM, Nesbakken A, Johannessen B, Lothe RA, Sveen A.

Cancer Lett. 2019 Oct 31. pii: S0304-3835(19)30543-9. doi: 10.1016/j.canlet.2019.10.040. [Epub ahead of print]

2.

Truncated PPM1D impairs stem cell response to genotoxic stress and promotes growth of APC-deficient tumors in the mouse colon.

Burocziova M, Burdova K, Martinikova AS, Kasparek P, Kleiblova P, Danielsen SA, Borecka M, Jenikova G, Janečková L, Pavel J, Zemankova P, Schneiderova M, Schwarzova L, Ticha I, Sun XF, Jiraskova K, Liska V, Vodickova L, Vodicka P, Sedlacek R, Kleibl Z, Lothe RA, Korinek V, Macurek L.

Cell Death Dis. 2019 Oct 28;10(11):818. doi: 10.1038/s41419-019-2057-4.

3.

Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2.

Lopes N, Bergsland CH, Bjørnslett M, Pellinen T, Svindland A, Nesbakken A, Almeida R, Lothe RA, David L, Bruun J.

Lab Invest. 2019 Oct 22. doi: 10.1038/s41374-019-0336-4. [Epub ahead of print]

PMID:
31641225
4.

Correction: Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage.

Glaire MA, Domingo E, Sveen A, Bruun J, Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W, Danielsen HE, Kerr R, Kerr D, Tomlinson I, Lothe RA, Church DN.

Br J Cancer. 2019 Oct;121(9):807. doi: 10.1038/s41416-019-0590-7.

PMID:
31548598
5.

Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer.

Carm KT, Hoff AM, Bakken AC, Axcrona U, Axcrona K, Lothe RA, Skotheim RI, Løvf M.

Sci Rep. 2019 Sep 19;9(1):13579. doi: 10.1038/s41598-019-49964-7.

6.

Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.

Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J.

Ann Oncol. 2019 Oct 1;30(10):1622-1629. doi: 10.1093/annonc/mdz287.

7.

Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage.

Glaire MA, Domingo E, Sveen A, Bruun J, Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W, Danielsen HE, Kerr R, Kerr D, Tomlinson I, Lothe RA, Church DN.

Br J Cancer. 2019 Sep;121(6):474-482. doi: 10.1038/s41416-019-0540-4. Epub 2019 Aug 7. Erratum in: Br J Cancer. 2019 Oct;121(9):807.

8.

Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases.

Brunsell TH, Cengija V, Sveen A, Bjørnbeth BA, Røsok BI, Brudvik KW, Guren MG, Lothe RA, Abildgaard A, Nesbakken A.

Eur J Surg Oncol. 2019 Dec;45(12):2340-2346. doi: 10.1016/j.ejso.2019.07.017. Epub 2019 Jul 17.

9.

Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer.

Smeby J, Sveen A, Bergsland CH, Eilertsen IA, Danielsen SA, Eide PW, Hektoen M, Guren MG, Nesbakken A, Bruun J, Lothe RA.

ESMO Open. 2019 Jun 24;4(3):e000523. doi: 10.1136/esmoopen-2019-000523. eCollection 2019.

10.

Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains.

Berg KCG, Sveen A, Høland M, Alagaratnam S, Berg M, Danielsen SA, Nesbakken A, Søreide K, Lothe RA.

Oncogene. 2019 Aug;38(33):6109-6122. doi: 10.1038/s41388-019-0868-5. Epub 2019 Jul 15.

11.

Biomarker-guided therapy for colorectal cancer: strength in complexity.

Sveen A, Kopetz S, Lothe RA.

Nat Rev Clin Oncol. 2019 Jul 9. doi: 10.1038/s41571-019-0241-1. [Epub ahead of print] Review.

PMID:
31289352
12.

Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer.

Smeby J, Sveen A, Eilertsen IA, Danielsen SA, Hoff AM, Eide PW, Johannessen B, Hektoen M, Skotheim RI, Guren MG, Nesbakken A, Lothe RA.

Oncogenesis. 2019 May 15;8(6):35. doi: 10.1038/s41389-019-0141-3.

13.

Characterization of early recurrences following liver resection by ALPPS and two stage hepatectomy in patients with colorectal liver-metastases and small future liver remnants; a translational substudy of the LIGRO-RCT.

Røsok BI, Høst-Brunsell T, Brudvik KW, Carling U, Dorenberg E, Björnsson B, Lothe RA, Bjørnbeth BA, Sandström P.

HPB (Oxford). 2019 Aug;21(8):1017-1023. doi: 10.1016/j.hpb.2018.12.003. Epub 2019 Feb 11.

PMID:
30765198
14.

Combination therapies with HSP90 inhibitors against colorectal cancer.

Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA.

Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):240-247. doi: 10.1016/j.bbcan.2019.01.002. Epub 2019 Jan 30. Review.

15.

Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell-intrinsic properties.

Eide PW, Eilertsen IA, Sveen A, Lothe RA.

Int J Cancer. 2019 Jun 1;144(11):2843-2853. doi: 10.1002/ijc.31998. Epub 2019 Jan 12.

16.

Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.

Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI.

Eur Urol. 2019 Mar;75(3):498-505. doi: 10.1016/j.eururo.2018.08.009. Epub 2018 Sep 1.

PMID:
30181068
17.

Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer.

Eilertsen IA, Sveen A, Strømme JM, Skotheim RI, Nesbakken A, Lothe RA.

Int J Cancer. 2019 Feb 15;144(4):841-847. doi: 10.1002/ijc.31809. Epub 2018 Oct 30.

18.

Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53.

Høland M, Kolberg M, Danielsen SA, Bjerkehagen B, Eilertsen IA, Hektoen M, Mandahl N, van den Berg E, Smeland S, Mertens F, Sundby Hall K, Picci P, Sveen A, Lothe RA.

Mod Pathol. 2018 Nov;31(11):1694-1707. doi: 10.1038/s41379-018-0074-y. Epub 2018 Jun 26.

19.

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.

Bruun J, Sveen A, Barros R, Eide PW, Eilertsen I, Kolberg M, Pellinen T, David L, Svindland A, Kallioniemi O, Guren MG, Nesbakken A, Almeida R, Lothe RA.

Mol Oncol. 2018 Sep;12(9):1639-1655. doi: 10.1002/1878-0261.12347. Epub 2018 Aug 15.

20.

Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer.

Vedeld HM, Nesbakken A, Lothe RA, Lind GE.

Clin Epigenetics. 2018 May 29;10:70. doi: 10.1186/s13148-018-0503-2. eCollection 2018.

21.

CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.

Smeby J, Sveen A, Merok MA, Danielsen SA, Eilertsen IA, Guren MG, Dienstmann R, Nesbakken A, Lothe RA.

Ann Oncol. 2018 May 1;29(5):1227-1234. doi: 10.1093/annonc/mdy085.

22.

A robust internal control for high-precision DNA methylation analyses by droplet digital PCR.

Pharo HD, Andresen K, Berg KCG, Lothe RA, Jeanmougin M, Lind GE.

Clin Epigenetics. 2018 Feb 21;10:24. doi: 10.1186/s13148-018-0456-5. eCollection 2018.

23.

The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer.

Oltedal S, Kørner H, Aasprong OG, Hussain I, Tjensvoll K, Smaaland R, Søreide JA, Søreide K, Lothe RA, Heikkilä R, Gilje B, Nordgård O.

Transl Oncol. 2018 Apr;11(2):436-443. doi: 10.1016/j.tranon.2018.01.015. Epub 2018 Feb 21.

24.

Prognostic markers for colorectal cancer: estimating ploidy and stroma.

Danielsen HE, Hveem TS, Domingo E, Pradhan M, Kleppe A, Syvertsen RA, Kostolomov I, Nesheim JA, Askautrud HA, Nesbakken A, Lothe RA, Svindland A, Shepherd N, Novelli M, Johnstone E, Tomlinson I, Kerr R, Kerr DJ.

Ann Oncol. 2018 Mar 1;29(3):616-623. doi: 10.1093/annonc/mdx794.

25.

Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.

Sveen A, Bruun J, Eide PW, Eilertsen IA, Ramirez L, Murumägi A, Arjama M, Danielsen SA, Kryeziu K, Elez E, Tabernero J, Guinney J, Palmer HG, Nesbakken A, Kallioniemi O, Dienstmann R, Lothe RA.

Clin Cancer Res. 2018 Feb 15;24(4):794-806. doi: 10.1158/1078-0432.CCR-17-1234. Epub 2017 Dec 14.

26.

CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models.

Eide PW, Bruun J, Lothe RA, Sveen A.

Sci Rep. 2017 Nov 30;7(1):16618. doi: 10.1038/s41598-017-16747-x.

27.

Prognostic relevance of an epigenetic biomarker panel in sentinel lymph nodes from colon cancer patients.

Lind GE, Guriby M, Ahlquist T, Hussain I, Jeanmougin M, Søreide K, Kørner H, Lothe RA, Nordgård O.

Clin Epigenetics. 2017 Sep 5;9:97. doi: 10.1186/s13148-017-0397-4. eCollection 2017.

28.

C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.

Landskron J, Kraggerud SM, Wik E, Dørum A, Bjørnslett M, Melum E, Helland Ø, Bjørge L, Lothe RA, Salvesen HB, Taskén K.

PLoS One. 2017 Jul 31;12(7):e0182030. doi: 10.1371/journal.pone.0182030. eCollection 2017.

29.

The E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin 43 to promote loss of gap junctions.

Totland MZ, Bergsland CH, Fykerud TA, Knudsen LM, Rasmussen NL, Eide PW, Yohannes Z, Sørensen V, Brech A, Lothe RA, Leithe E.

J Cell Sci. 2017 Sep 1;130(17):2867-2882. doi: 10.1242/jcs.202408. Epub 2017 Jul 21.

30.

Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies.

Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA.

Mol Cancer. 2017 Jul 6;16(1):116. doi: 10.1186/s12943-017-0691-y.

31.

Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.

Kolberg M, Bruun J, Murumägi A, Mpindi JP, Bergsland CH, Høland M, Eilertsen IA, Danielsen SA, Kallioniemi O, Lothe RA.

Mol Oncol. 2017 Sep;11(9):1156-1171. doi: 10.1002/1878-0261.12086. Epub 2017 Jul 5.

32.

CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.

Vedeld HM, Merok M, Jeanmougin M, Danielsen SA, Honne H, Presthus GK, Svindland A, Sjo OH, Hektoen M, Eknaes M, Nesbakken A, Lothe RA, Lind GE.

Int J Cancer. 2017 Sep 1;141(5):967-976. doi: 10.1002/ijc.30796. Epub 2017 Jun 2.

33.

Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1.

Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA.

Genome Med. 2017 May 24;9(1):46. doi: 10.1186/s13073-017-0434-0.

34.

Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Dienstmann R, Mason MJ, Sinicrope FA, Phipps AI, Tejpar S, Nesbakken A, Danielsen SA, Sveen A, Buchanan DD, Clendenning M, Rosty C, Bot B, Alberts SR, Milburn Jessup J, Lothe RA, Delorenzi M, Newcomb PA, Sargent D, Guinney J.

Ann Oncol. 2017 May 1;28(5):1023-1031. doi: 10.1093/annonc/mdx052.

35.

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20.

PMID:
28404093
36.

Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1.

Ramalho-Carvalho J, Martins JB, Cekaite L, Sveen A, Torres-Ferreira J, Graça I, Costa-Pinheiro P, Eilertsen IA, Antunes L, Oliveira J, Lothe RA, Henrique R, Jerónimo C.

Cancer Lett. 2017 Jan 28;385:150-159. doi: 10.1016/j.canlet.2016.10.028. Epub 2016 Oct 27.

PMID:
27984115
37.

Mitotic cells form actin-based bridges with adjacent cells to provide intercellular communication during rounding.

Fykerud TA, Knudsen LM, Totland MZ, Sørensen V, Dahal-Koirala S, Lothe RA, Brech A, Leithe E.

Cell Cycle. 2016 Nov;15(21):2943-2957. Epub 2016 Sep 13.

38.

Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.

Sveen A, Løes IM, Alagaratnam S, Nilsen G, Høland M, Lingjærde OC, Sorbye H, Berg KC, Horn A, Angelsen JH, Knappskog S, Lønning PE, Lothe RA.

PLoS Genet. 2016 Jul 29;12(7):e1006225. doi: 10.1371/journal.pgen.1006225. eCollection 2016 Jul.

39.

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.

Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA.

Oncotarget. 2016 Feb 2;7(5):5273-88. doi: 10.18632/oncotarget.6567.

40.

Identification of Novel Fusion Genes in Testicular Germ Cell Tumors.

Hoff AM, Alagaratnam S, Zhao S, Bruun J, Andrews PW, Lothe RA, Skotheim RI.

Cancer Res. 2016 Jan 1;76(1):108-16. doi: 10.1158/0008-5472.CAN-15-1790. Epub 2015 Dec 9.

41.

MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.

Cekaite L, Eide PW, Lind GE, Skotheim RI, Lothe RA.

Oncotarget. 2016 Feb 9;7(6):6476-505. doi: 10.18632/oncotarget.6390. Review.

42.

Novel RNA variants in colorectal cancers.

Hoff AM, Johannessen B, Alagaratnam S, Zhao S, Nome T, Løvf M, Bakken AC, Hektoen M, Sveen A, Lothe RA, Skotheim RI.

Oncotarget. 2015 Nov 3;6(34):36587-602. doi: 10.18632/oncotarget.5500.

43.

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Sveen A, Kilpinen S, Ruusulehto A, Lothe RA, Skotheim RI.

Oncogene. 2016 May 12;35(19):2413-27. doi: 10.1038/onc.2015.318. Epub 2015 Aug 24. Review.

PMID:
26300000
44.

Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer.

Bruun J, Kolberg M, Ahlquist TC, Røyrvik EC, Nome T, Leithe E, Lind GE, Merok MA, Rognum TO, Bjørkøy G, Johansen T, Lindblom A, Sun XF, Svindland A, Liestøl K, Nesbakken A, Skotheim RI, Lothe RA.

Clin Cancer Res. 2015 Aug 15;21(16):3759-70. doi: 10.1158/1078-0432.CCR-14-3294. Epub 2015 Apr 24.

45.

Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection.

Kolberg M, Høland M, Lind GE, Ågesen TH, Skotheim RI, Hall KS, Mandahl N, Smeland S, Mertens F, Davidson B, Lothe RA.

Mol Oncol. 2015 Jun;9(6):1129-39. doi: 10.1016/j.molonc.2015.02.005. Epub 2015 Feb 18.

46.

Exome sequencing of bilateral testicular germ cell tumors suggests independent development lineages.

Brabrand S, Johannessen B, Axcrona U, Kraggerud SM, Berg KG, Bakken AC, Bruun J, Fosså SD, Lothe RA, Lehne G, Skotheim RI.

Neoplasia. 2015 Feb;17(2):167-74. doi: 10.1016/j.neo.2014.12.005.

47.

Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma.

Andresen K, Boberg KM, Vedeld HM, Honne H, Jebsen P, Hektoen M, Wadsworth CA, Clausen OP, Lundin KE, Paulsen V, Foss A, Mathisen Ø, Aabakken L, Schrumpf E, Lothe RA, Lind GE.

Hepatology. 2015 May;61(5):1651-9. doi: 10.1002/hep.27707. Epub 2015 Feb 24.

48.

Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.

Mesquita D, Barros-Silva JD, Santos J, Skotheim RI, Lothe RA, Paulo P, Teixeira MR.

Oncotarget. 2015 Mar 10;6(7):5217-36.

49.

Portrait of the PI3K/AKT pathway in colorectal cancer.

Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA.

Biochim Biophys Acta. 2015 Jan;1855(1):104-21. doi: 10.1016/j.bbcan.2014.09.008. Epub 2014 Nov 22. Review.

PMID:
25450577
50.

Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.

Almeida M, Costa VL, Costa NR, Ramalho-Carvalho J, Baptista T, Ribeiro FR, Paulo P, Teixeira MR, Oliveira J, Lothe RA, Lind GE, Henrique R, Jerónimo C.

J Cell Mol Med. 2014 Nov;18(11):2287-97. doi: 10.1111/jcmm.12394. Epub 2014 Sep 11.

Supplemental Content

Loading ...
Support Center